Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2543049 | 1.00 | KCNH2 (0.44) | KCNH2SLC2A1JAK2JAK1MAP4K4 | |
| SCHEMBL3452206 | 0.92 | JAK1 (0.40) | KCNH2SLC2A1JAK2JAK1MAP4K4 | |
| SCHEMBL3452208 | 0.92 | JAK1 (0.40) | KCNH2SLC2A1JAK2JAK1MAP4K4 | |
| SCHEMBL16650253 | 0.91 | KCNH2 (0.43) | KCNH2SLC2A1JAK2JAK1MAP4K4 | |
| SCHEMBL3597040 | 0.91 | KCNH2 (0.43) | KCNH2SLC2A1JAK2JAK1MAP4K4 | |
| SCHEMBL16650254 | 0.91 | KCNH2 (0.43) | KCNH2SLC2A1JAK2JAK1MAP4K4 | |
| SCHEMBL16650256 | 0.91 | KCNH2 (0.43) | KCNH2SLC2A1JAK2JAK1MAP4K4 | |
| SCHEMBL2539625 | 0.90 | KCNH2 (0.42) | KCNH2SLC2A1JAK2JAK1MAP4K4 | |
| SCHEMBL2537316 | 0.90 | KCNH2 (0.42) | KCNH2SLC2A1JAK2JAK1MAP4K4 | |
| SCHEMBL2539623 | 0.90 | KCNH2 (0.42) | KCNH2SLC2A1JAK2JAK1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094267-B1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-8044044-B2 | 4-(1-amino-ethyl)-cyclohexylamine derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-25 | — | — | US | disclosed |
| EP-1987040-B1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20100029623-A1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029623-A1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | AHR, KRAS, CNKSR1 | KCNH2 296/4885SLC2A1 4234/4885JAK2 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.